Warning: mysql_query(): Unable to save result set in /home/ttpcom/public_html/wp-includes/wp-db.php on line 1870
Healthcare Startup Remidio Raises Series B Round Led By Cipher-Plexus Capital Advisors | The Tech Portal

Healthcare Startup Remidio Raises Series B Round Led By Cipher-Plexus Capital Advisors

remidio
Share on Facebook
Tweet about this on TwitterShare on Google+Share on StumbleUponShare on LinkedInPin on PinterestShare on Reddit

Remidio, a Bangalore-based startup which is providing affordable healthcare product solutions, has raised an undisclosed amount of funding in its Series B round of funding, from a group of angel investors and Cipher-Plexus Capital Advisors.

The company was founded in 2009 by Anand Sivaraman and Pramod Kummaya. Remidio is an ophthalmic products company that aims to bring out affordable products.

Remidio’s vision is to bring to market ophthalmic devices that are affordable, easy-to-use and built with a larger aim of tackling avoidable blindness in resource-starved situations.

It is currently offering two products – a smartphone based ‘Fundus on Phone’ (FOP) which ‘piggyback’ onto a regular smartphone and takes high resolution images of the back of the eye; and Angio on Touch (AOT) which is a diagnostic imaging system.

Anand Sivaraman, CEO & co-founder, Remidio said,

There is a huge demand for eye wellness technologies that are simple to use, high quality, and telemedicine enabled over the smartphone. With the current round of funding, we will aggressively scale the business in both the Indian and International markets.

The company’s mission is to create highly innovative products that can challenge existing paradigms in public health. It’s vision is to bring to market ophthalmic devices that are affordable, easy-to-use and built with a larger aim of tackling avoidable blindness in resource-starved situations.


[email protected]



Warning: mysql_query(): Unable to save result set in /home/ttpcom/public_html/wp-includes/wp-db.php on line 1870

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *